We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.07%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$705M
AUM Growth
+$41.3M
Cap. Flow
+$7.11M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.32%
Holding
99
New
15
Increased
51
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$24.2M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$16.8M
3
CLSD
Clearside Biomedical
CLSD
+$13.9M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.94M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$8.79M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$23.9M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.6M
3
CELG
Celgene Corp
CELG
+$10M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$9.47M
5
RMTI icon
Rockwell Medical
RMTI
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$42.2M 5.98%
1,689,071
+191,596
+13% +$5.18M
NVRO
2
DELISTED
NEVRO CORP.
NVRO
$36.2M 5.14%
491,044
+5,658
+1% +$384K
HRTX icon
3
Heron Therapeutics
HRTX
$94.1M
$32M 4.53%
1,771,263
+21,263
+1% +$415K
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$30.5M 4.33%
362,875
+71,625
+25% +$3.19M
NKTR icon
5
Nektar Therapeutics
NKTR
$2.41B
$28.8M 4.08%
134,859
+1,526
+1% +$341K
NERV icon
6
Minerva Neurosciences
NERV
$187M
$28.6M 4.05%
350,000
+130,882
+60% +$8.32M
TBPH icon
7
Theravance Biopharma
TBPH
$873M
$25.4M 3.6%
+1,118,372
New +$24.2M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$22M 3.12%
730,000
-215,000
-23% -$7.17M
EGRX
9
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$19.6M 2.78%
505,995
+5,995
+1% +$250K
MGNX icon
10
MacroGenics
MGNX
$240M
$19.1M 2.71%
707,978
+7,978
+1% +$180K
VTAE
11
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$18.9M 2.69%
1,754,795
+19,795
+1% +$169K
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$18.3M 2.6%
+334,044
New +$16.8M
NBIX icon
13
Neurocrine Biosciences
NBIX
$18.7B
$18.1M 2.57%
398,301
-205,599
-34% -$9.47M
OMER icon
14
Omeros
OMER
$863M
$18M 2.55%
1,710,000
-250,000
-13% -$3.08M
ACRS icon
15
Aclaris Therapeutics
ACRS
$743M
$16.6M 2.36%
901,286
+253,342
+39% +$5.02M
KA
16
DELISTED
Kineta, Inc. Common Stock
KA
$16.4M 2.33%
9,674
-2,659
-22% -$4.84M
CLSD
17
DELISTED
Clearside Biomedical
CLSD
$13.9M 1.98%
+132,547
New +$13.9M
CLLS
18
Cellectis
CLLS
$287M
$13.2M 1.88%
498,117
+28,972
+6% +$849K
ARDX icon
19
Ardelyx
ARDX
$1.25B
$13.1M 1.86%
1,499,226
+18,151
+1% +$148K
CBPO
20
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$12M 1.7%
112,867
+1,367
+1% +$159K
QTNT
21
DELISTED
Quotient Limited Ordinary Shares
QTNT
$11.9M 1.69%
38,443
+465
+1% +$178K
SRNE
22
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$11.9M 1.68%
2,121,013
+25,679
+1% +$164K
NVAX icon
23
Novavax
NVAX
$1.22B
$11.8M 1.67%
80,980
+980
+1% +$112K
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$27.4B
$11.1M 1.58%
200,355
-44,645
-18% -$2.81M
CHRS icon
25
Coherus Oncology
CHRS
$227M
$9.73M 1.38%
576,106
+6,976
+1% +$131K
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Cormorant Asset Management held 99 positions worth $705M, up 6.2% from $664M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cormorant Asset Management's Q2 2016 filing shows 15 new, 51 increased, 12 reduced and 16 closed positions. Its largest new stake was Theravance Biopharma: 1,118,372 shares worth $25.4M. The largest sale was Alkermes, an estimated $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier.

  • Cormorant Asset Management's largest Q2 2016 buy was Theravance Biopharma: 1,118,372 shares worth $25.4M.
  • Cormorant Asset Management added most to Minerva Neurosciences in Q2 2016, an estimated $8.32M increase.
  • Cormorant Asset Management's biggest Q2 2016 reduction was Neurocrine Biosciences, cutting an estimated $9.47M.
  • Cormorant Asset Management fully exited Alkermes in Q2 2016, selling an estimated $23.9M.
  • Cormorant Asset Management's ten largest holdings make up 40% of its $705M portfolio in Q2 2016.
  • Cormorant Asset Management opened 15 new positions and closed 16 in Q2 2016.
  • Cormorant Asset Management's portfolio value rose 6.2% quarter-over-quarter to $705M.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.